Unicycive Therapeutics Inc (UNCY)
Unicycive Therapeutics, Inc. is a clinical-stage biotechnology company focused on identifying, developing, and commercializing therapies for unmet medical needs in the United States. Its development pipeline includes UNI 494, a pro-drug of nicorandil being studied for acute kidney injury, and Renazorb RZB 012, which is being developed to treat hyperphosphatemia in patients with chronic kidney disease. The company also reviews licensing opportunities involving technologies and drug candidates in orphan diseases as well as renal, liver, and other metabolic disorders linked to fibrosis and inflammation. Unicycive has entered into multiple license and collaboration agreements with partners including Shilpa Medicare Ltd, Sphaera Pharma Pte. Ltd., Syneos Health LLC, Inotiv, Lee’s Pharmaceutical (HK) Limited, and Lotus International Pte Ltd. Incorporated in 2016, the company is based in Los Altos, California.
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-UNCY
|
$4.50
|
-17.8% Downside
|
Fair
|
$38.59
|
605.5% Upside
|
Bargain
|
Fair
|
—
|
—
|
—
|
0.0%
|
August 17, 2026
|
-3.7x
|
4.0x
|
—
|
149.3 M
|
95.795 M
|
0.5%
|
91.2%
|
-0.5
|
—
|
71.9%
|
